-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10

Benzinga·06/11/2026 09:46:50
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.